JP2011530531A5 - - Google Patents

Download PDF

Info

Publication number
JP2011530531A5
JP2011530531A5 JP2011522250A JP2011522250A JP2011530531A5 JP 2011530531 A5 JP2011530531 A5 JP 2011530531A5 JP 2011522250 A JP2011522250 A JP 2011522250A JP 2011522250 A JP2011522250 A JP 2011522250A JP 2011530531 A5 JP2011530531 A5 JP 2011530531A5
Authority
JP
Japan
Prior art keywords
pyrrolidinyl
benzimidazol
benzimidazole
ethynyl
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011522250A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011530531A (ja
JP5599792B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/053019 external-priority patent/WO2010017401A1/en
Publication of JP2011530531A publication Critical patent/JP2011530531A/ja
Publication of JP2011530531A5 publication Critical patent/JP2011530531A5/ja
Application granted granted Critical
Publication of JP5599792B2 publication Critical patent/JP5599792B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011522250A 2008-08-07 2009-08-06 C型肝炎ウイルス阻害剤としてのbi−1h−ベンズアミダゾール Expired - Fee Related JP5599792B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8707808P 2008-08-07 2008-08-07
US61/087,078 2008-08-07
PCT/US2009/053019 WO2010017401A1 (en) 2008-08-07 2009-08-06 Bi-1h-benzimidazoles as hepatitis c virus inhibitors

Publications (3)

Publication Number Publication Date
JP2011530531A JP2011530531A (ja) 2011-12-22
JP2011530531A5 true JP2011530531A5 (https=) 2012-08-16
JP5599792B2 JP5599792B2 (ja) 2014-10-01

Family

ID=41314575

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011522250A Expired - Fee Related JP5599792B2 (ja) 2008-08-07 2009-08-06 C型肝炎ウイルス阻害剤としてのbi−1h−ベンズアミダゾール

Country Status (5)

Country Link
US (1) US7906655B2 (https=)
EP (1) EP2318376B1 (https=)
JP (1) JP5599792B2 (https=)
CN (2) CN104072486B (https=)
WO (1) WO2010017401A1 (https=)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009006567A2 (en) * 2007-07-05 2009-01-08 Array Biopharma Inc. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
EA201071034A1 (ru) * 2008-04-15 2011-06-30 Интермьюн, Инк. Новые макроциклические ингибиторы репликаций вируса гепатита с
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
WO2010065674A1 (en) * 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
CA2750577A1 (en) * 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
SG172352A1 (en) 2008-12-23 2011-07-28 Abbott Lab Anti-viral compounds
US8546405B2 (en) * 2008-12-23 2013-10-01 Abbott Laboratories Anti-viral compounds
EP2393359A4 (en) * 2009-02-09 2012-10-03 Enanta Pharm Inc COMPOUND DIBENZIMIDAZOLE DERIVATIVES
US8314135B2 (en) * 2009-02-09 2012-11-20 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole antivirals
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI438200B (zh) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 C型肝炎病毒抑制劑
US8637561B2 (en) 2009-02-17 2014-01-28 Enanta Pharmaceuticals, Inc. Linked diimidazole derivatives
US8420686B2 (en) 2009-02-17 2013-04-16 Enanta Pharmaceuticals, Inc. Linked diimidazole antivirals
US8242156B2 (en) 2009-02-17 2012-08-14 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8188132B2 (en) * 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8673954B2 (en) 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US9765087B2 (en) 2009-02-27 2017-09-19 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8101643B2 (en) 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8426458B2 (en) 2009-02-27 2013-04-23 Enanta Pharmaceuticals, Inc. Hepatitis C Virus inhibitors
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US8507522B2 (en) 2009-03-06 2013-08-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) * 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9278922B2 (en) * 2009-04-15 2016-03-08 Abbvie Inc. Anti-viral compounds
EP2430015B1 (en) 2009-05-12 2015-06-17 Merck Sharp & Dohme Corp. Fused tricyclic compounds useful for the treatment of viral diseases
HUE030465T2 (hu) * 2009-05-13 2017-05-29 Antivirális vegyületek
AU2013202666B2 (en) * 2009-05-13 2015-07-16 Gilead Sciences, Inc. Antiviral compounds
AU2014203349B2 (en) * 2009-05-13 2014-11-27 Gilead Sciences, Inc. Antiviral compounds
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2435421A1 (en) 2009-05-29 2012-04-04 Schering Corporation Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2012528195A (ja) 2009-05-29 2012-11-12 メルク・シャープ・アンド・ドーム・コーポレーション C型肝炎などの疾患を処置するための3つの結合アリール部分で構成された抗菌性化合物
AU2012203474B2 (en) * 2009-06-11 2014-09-18 Abbvie Ireland Unlimited Company Anti-Viral Compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
EA020031B1 (ru) * 2009-06-11 2014-08-29 Эббви Бахамаз Лтд. Противовирусные соединения
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8609648B2 (en) 2009-07-02 2013-12-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
AU2010274001A1 (en) 2009-07-16 2012-02-23 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of Flavivirus infections
WO2011015658A1 (en) 2009-08-07 2011-02-10 Tibotec Pharmaceuticals Bis-benzimidazole derivatives as hepatitis c virus inhibitors
AU2010291215A1 (en) 2009-09-03 2012-02-23 Janssen Sciences Ireland Uc Bis-benzimidazole derivatives
CN102480971B (zh) 2009-09-04 2014-11-26 杨森制药公司 化合物
US8815928B2 (en) 2009-09-11 2014-08-26 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8759332B2 (en) 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US9156818B2 (en) 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8927709B2 (en) 2009-09-11 2015-01-06 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8703938B2 (en) 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
IN2012DN02693A (https=) * 2009-09-28 2015-09-04 Intermune Inc
UA108211C2 (uk) * 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
EP2503881B1 (en) * 2009-11-25 2015-05-13 Merck Sharp & Dohme Corp. Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
US20110137633A1 (en) * 2009-12-03 2011-06-09 Abbott Laboratories Anti-viral compounds and methods of identifying the same
US8653070B2 (en) 2009-12-14 2014-02-18 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MX2012006877A (es) 2009-12-18 2012-08-31 Idenix Pharmaceuticals Inc Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado.
AU2010341537A1 (en) 2009-12-22 2012-08-09 Merck Sharp & Dohme Corp. Fused Tricyclic Compounds and methods of use thereof for the treatment of viral diseases
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
PE20130244A1 (es) 2010-01-25 2013-03-10 Enanta Pharm Inc Inhibidores del virus de la hepatitis c
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
US8178531B2 (en) 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
CN102858157A (zh) * 2010-03-04 2013-01-02 埃南塔制药公司 作为hcv复制的抑制剂的组合药物活性剂
EP2545060B1 (en) * 2010-03-09 2015-11-25 Merck Sharp & Dohme Corp. Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
CN102869657A (zh) 2010-03-24 2013-01-09 沃泰克斯药物股份有限公司 用于治疗或预防黄病毒感染的类似物
AU2011232348A1 (en) * 2010-03-24 2012-10-11 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of Flavivirus infections
EP2555622A4 (en) 2010-04-09 2013-09-18 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US20130296311A1 (en) * 2010-05-28 2013-11-07 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
ES2803556T3 (es) 2010-06-01 2021-01-27 Summit Oxford Ltd Compuestos para el tratamiento de enfermedades asociadas a clostridium difficile
WO2011151620A1 (en) * 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
US8778938B2 (en) 2010-06-04 2014-07-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
AR081848A1 (es) * 2010-06-09 2012-10-24 Presidio Pharmaceuticals Inc Inhibidores de la proteina ns5a del vhc
NZ605440A (en) * 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
WO2012006060A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
EP2585447A2 (en) 2010-06-28 2013-05-01 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
CN103180310B (zh) 2010-07-26 2015-11-25 爱尔兰詹森科学公司 作为hcv抑制剂的杂二环衍生物
WO2012021704A1 (en) 2010-08-12 2012-02-16 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
EP2606041A2 (en) 2010-08-17 2013-06-26 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flaviviridae viral infections
US8859595B2 (en) 2010-08-26 2014-10-14 Rfs Pharma, Llc Potent and selective inhibitors of hepatitis C virus
AU2014203655B2 (en) * 2010-10-13 2016-07-07 Abbvie Ireland Unlimited Company Anti-viral compounds
SG189985A1 (en) 2010-10-26 2013-06-28 Presidio Pharmaceuticals Inc Inhibitors of hepatitis c virus
EP2651923A4 (en) * 2010-12-15 2014-06-18 Abbvie Inc ANTI-VIRAL COMPOUNDS
EP2651928A4 (en) * 2010-12-15 2014-06-18 Abbvie Inc ANTI-VIRAL COMPOUNDS
WO2012083164A1 (en) * 2010-12-16 2012-06-21 Abbott Laboratories Anti-viral compounds
CA2822357A1 (en) 2010-12-22 2012-06-28 Abbvie Inc. Hepatitis c inhibitors and uses thereof
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2012158861A2 (en) 2011-05-18 2012-11-22 Enanta Pharmaceuticals, Inc. Processes for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives
AU2012286853A1 (en) 2011-07-26 2013-05-02 Vertex Pharmaceuticals Incorporated Thiophene compounds
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
EP2709613B2 (en) 2011-09-16 2020-08-12 Gilead Pharmasset LLC Methods for treating hcv
AU2012360910B8 (en) 2011-12-28 2017-02-02 Janssen Sciences Ireland Uc Quinazolinone derivatives as HCV inhibitors
MX340033B (es) 2011-12-28 2016-06-21 Janssen Sciences Ireland Uc Derivados heterobiciclicos como inhibidores del virus de la hepatitis c.
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
ES2802251T3 (es) 2012-01-06 2021-01-18 Novartis Ag Compuestos heterocíclicos y métodos para su uso
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
WO2014055069A1 (en) * 2012-10-02 2014-04-10 Presidio Pharmaceuticals, Inc. Solid forms comprising an inhibitor of hcv ns5a, compositions thereof, and uses therewith
EP2950786B1 (en) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
RU2518369C1 (ru) * 2013-02-07 2014-06-10 Общество с ограниченной ответственностью "Интеллектуальный Диалог" Алкил [2-(2-{5-[4-(4-{2-[1-(2-метоксикарбониламино-ацетил)-пирролидин-2-ил]-3н-имидазол-4-ил}-фенил)-бута-1,3-диинил]-1н-имидазол-2-ил}-пирролидин-1-ил)-2-оксо-этил]-карбамат, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний
RU2507201C1 (ru) * 2013-02-07 2014-02-20 Александр Васильевич Иващенко Алкил [(s)-1-((s)-2-{5-[4-(4-{2-[(s)-1-((s)-2-метоксикарбониламино-3-метил-бутирил)-пирролидин-2-ил]-3н-имидазол-4-ил}-бута-1,3-диинил)-фенил]-1н-имидазол-2-ил}-пирролидин-1-карбонил)-2-метил-пропил]-карбамат нафталин-1,5-дисульфонат, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний
WO2014134251A1 (en) 2013-02-28 2014-09-04 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
PT3038601T (pt) 2013-08-27 2020-06-30 Gilead Pharmasset Llc Formulação combinada de dois compostos antivirais
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
JP6667551B2 (ja) 2015-01-13 2020-03-18 ノバルティス アーゲー アンジオテンシンii2型拮抗薬としてのピロリジン誘導体
WO2017023631A1 (en) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
KR102835299B1 (ko) 2018-12-04 2025-07-18 브리스톨-마이어스 스큅 컴퍼니 다중 동위원소체 반응 모니터링에 의한 샘플내 보정 곡선을 사용한 분석 방법
US12037340B2 (en) 2021-05-21 2024-07-16 Gilead Sciences, Inc. Pentacyclic derivatives as Zika virus inhibitors
US12497408B2 (en) 2021-05-21 2025-12-16 Gilead Sciences, Inc. Tetracyclic compounds and methods for the treatment of Zika virus infection

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08505854A (ja) 1993-01-14 1996-06-25 マガイニン ファーマシューティカルズ,インク. 修飾された末端を有するアミノ酸及びペプチド
US5654451B1 (en) * 1993-01-14 2000-02-22 Magainin Pharma Amino acids and peptides having modified c-terminals and modified n-terminals
US5830905A (en) * 1996-03-29 1998-11-03 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
AU1099000A (en) * 1998-10-05 2000-04-26 Axys Pharmaceuticals, Inc. Novel compounds and compositions for treating hepatitis c infections
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
AU2002228317A1 (en) * 2001-01-29 2002-08-12 Insight Strategy And Marketing Ltd Benz-1,3-azole derivatives and their uses as heparanase inhibitors
WO2006022442A1 (ja) 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
WO2006093867A1 (en) 2005-02-28 2006-09-08 The Rockefeller University Structure of the hepatitits c virus ns5a protein
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
EP1940786B1 (en) 2005-09-16 2010-08-18 Arrow Therapeutics Limited Biphenyl derivatives and their use in treating hepatitis c
WO2007058384A1 (en) 2005-11-17 2007-05-24 Osaka University Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same
SG133452A1 (en) 2005-12-30 2007-07-30 Novartis Ag Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases
KR20090012345A (ko) 2006-05-30 2009-02-03 애로우 쎄라퓨틱스 리미티드 바이페닐 유도체, 및 c형 간염 치료에 있어서의 이들의 용도
ES2745411T3 (es) 2006-07-27 2020-03-02 Wang Nai Fang Compuestos y composiciones de arilsulfanilo para administración de agentes activos
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8236950B2 (en) 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
PT2114896E (pt) * 2006-12-21 2015-11-04 Peter Maccallum Cancer Inst Compostos radio-protetores e métodos relacionados
US8629171B2 (en) 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
US7728027B2 (en) 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
WO2009043902A1 (en) * 2007-10-05 2009-04-09 Universite De Mons Hainaut Bisbenzimidazoles as antimalarial agents
DK2250163T3 (da) 2008-02-12 2012-07-16 Bristol Myers Squibb Co Hepatitis C-virusinhibitorer
KR20100123717A (ko) 2008-02-12 2010-11-24 브리스톨-마이어스 스큅 컴퍼니 C형 간염 바이러스 억제제로서의 헤테로시클릭 유도체
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2009102325A1 (en) 2008-02-13 2009-08-20 Bristol-Myers Squibb Company Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors

Similar Documents

Publication Publication Date Title
JP2011530531A5 (https=)
JP2013510853A5 (https=)
JP2012518000A5 (https=)
HRP20120706T1 (hr) Imidazolil bifenil imidazoli kao inhibitori virusa hepatitisa c
JP2010500415A5 (https=)
JP2012528161A5 (https=)
HRP20130063T1 (hr) Inhibitori virusa hepatitisa c
JP2010500414A5 (https=)
JP2012523415A5 (https=)
HRP20120440T1 (hr) Inhibitori virusa hepatitisa c
JP2010500413A5 (https=)
JP2014513690A5 (https=)
JP2012522056A5 (https=)
JP2013510857A5 (https=)
HRP20140737T1 (hr) Inhibitori hepatitis c virusa
JP2013532725A5 (https=)
JP2012522053A5 (https=)
JP2010527373A5 (https=)
PE20121354A1 (es) Inhibidores del virus de la hepatitis c
JP2006525276A5 (https=)
PE20120546A1 (es) Inhibidores del virus de la hepatitis c
JP2012512169A5 (https=)
JP2011511841A5 (https=)
JP2012523457A5 (https=)
NZ606645A (en) Anti-viral compounds